Bayer Net Profit Falls on Lower Sales, Currency Headwinds
By Helena Smolak
Bayer posted a fall in first-quarter net profit on declining sales across all segments as well as currency headwinds.
The German pharmaceutical and agricultural company said Tuesday that net profit was 2 billion euros ($2.16 billion), down from EUR2.18 billion the previous year but above analysts' forecasts of EUR1.73 billion, according to a Vara Research consensus.
Earnings before interest, taxes, depreciation, amortization and special items declined to EUR4.41 billion from EUR4.47 billion while earnings before interest and taxes rose to EUR3.09 billion from EUR2.97 billion, Bayer said.
Sales declined 4.3% to EUR13.77 billion due to less demand across its pharmaceuticals, consumer health and crop science segments, missing a consensus forecast of EUR14.08 billion.
The company said sales at its agricultural business, crop science, fell 3% on an adjusted basis to EUR7.91 billion due to lower volumes for non-glyphosate-based herbicides and its fungicides business in Europe, Middle East and Africa. On an adjusted basis, sales at its pharmaceuticals division rose 3.9% to EUR4.36 billion, boosted by higher sales of its new cancer drug Nubeqa and its kidney disease treatment Kerendia, Bayer said.
The company backed its currency-adjusted 2024 guidance.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
May 14, 2024 02:13 ET (06:13 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks